Molecular-Driven Therapy in Advanced Thyroid Cancer

Kevin C. Miller, Ashish V. Chintakuntlawar

Research output: Contribution to journalReview articlepeer-review


With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to respond to immune checkpoint inhibition (i.e., PD-L1-positive tumors) and even priming responses to traditional therapies such as radioactive iodine (via concomitant MAPK pathway inhibition). There is also a growing role for genomics in the prognostication of thyroid tumors to aid the adjudication of appropriate treatments. Taking stock of the current state of the field, recent successes should be celebrated, but there still remains a long road ahead to improve outcomes for patients, particularly for radioactive-iodine refractory differentiated thyroid cancer and anaplastic thyroid cancer. In this review, we summarize findings from recent clinical trials and highlight promising preclinical data supporting molecular-driven therapy in advanced thyroid cancer. Ultimately, enrollment in clinical trials remains paramount to the advancement of thyroid cancer care.

Original languageEnglish (US)
Article number24
JournalCurrent treatment options in oncology
Issue number3
StatePublished - Mar 2021


  • Genomics
  • Immunotherapy
  • Targeted therapy
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Molecular-Driven Therapy in Advanced Thyroid Cancer'. Together they form a unique fingerprint.

Cite this